Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01091506 · ClinicalTrials.gov registry record · NA
A Placebo-Controlled Study of Physiologic Effects of L-methylfolate in Schizophrenia Patients
A NA study, sponsored by Pamlab.
- Completed
- Registry status
- NA
- Development phase
- 55
- Enrollment target
NCT01091506: Completed NA study, sponsored by Pamlab.
NCT01091506 is a NA study that has completed, run by Pamlab. The registered enrollment target is 55 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01091506, a NA study, has completed, sponsored by Pamlab.
- COMPLETED
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
Study Summary
This study is a 12-week, double-blind, placebo-controlled trial of L-methylfolate 15 mg/d supplementation in schizophrenia patients with mild or greater negative symptoms. L-methylfolate, a prescription medical food, is the activated form of folate required for conversion of homocysteine to methionine and hence is the optimal form of folate for supplementation, since it eliminates the need for activation by MTHFR. The purpose of this study is to examine the change in plasma L-methylfolate concentrations following a three-month trial of L-methylfolate 15 mg/d compared to placebo.
Interventions
- OTHER Placebo
- OTHER L-methylfolate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2010-03 |
| Est. Completion | 2014-06 |
| Phase | NA |
What the finished NCT01091506 record still lists
NCT01091506 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01091506 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01091506 about?
NCT01091506 is a clinical study titled "A Placebo-Controlled Study of Physiologic Effects of L-methylfolate in Schizophrenia Patients". This study is a 12-week, double-blind, placebo-controlled trial of L-methylfolate 15 mg/d supplementation in schizophrenia patients with mild or greater negative symptoms. L-methylfolate, a prescription medical food, is the activated form of folate required for conversion of homocysteine to methioni...
What is the current status of trial NCT01091506?
This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2010-03. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01091506?
The interventions under investigation include: Placebo (OTHER), L-methylfolate (OTHER).
Who is sponsoring clinical trial NCT01091506?
This trial is sponsored by Pamlab, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01091506's enrollment target sits among peer trials
55 1264th of 2000 higher than 733 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia